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Abstract
Numerous published papers are investigating the utility of biomarkers in 
Idiopathic Pulmonary Fibrosis (IPF) diagnosis, treatment, and outcome prediction. 
This chapter will summarize our current knowledge about biomarkers associated 
with alveolar epithelial cell damage and dysfunction (Krebs von den Lungen, 
surfactant proteins, the mucin MUC5B, CA 15-3, CA 125, CA 19-9, defensins, Clara 
cell protein (CC16), telomere shortening), biomarkers associated with fibrogenesis, 
fibroproliferation and extracellular matrix (ECM) remodeling (MMPs and their 
inhibitors, osteopontin, periostin, insulin-like growth factors, fibulin-1, heat shock 
protein 47, lysyl oxidase-like 2, circulating fibroblasts, extracellular matrix neoepi-
topes) and biomarkers related to immune dysfunction and inflammation (C-C che-
mokine ligand-18, C-C chemokine 2, YKL-40, C-X-C motif chemokine 13, S100A4, 
S100A8/9, S100A12, autoantibodies to heat shock protein 72, toll-like receptor 3, 
soluble receptor for advanced glycosylated end products, endothelial damage (vas-
cular endothelial growth factor, interleukin 8, endothelin 1). The future directions 
in incorporating IPF biomarkers into clinical practice will be reviewed.
Keywords: idiopathic pulmonary fibrosis, biomarkers, extracellular matrix, 
remodeling and fibroproliferation, alveolar epithelial cell dysfunction,  
immune dysfunction diagnosis, prognosis
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of 
unknown etiology, progressive and irreversible interstitial lung disease (ILD). IPF 
is the most common form of idiopathic interstitial pneumonia. It affects around 
3 million people worldwide [1]. The increasing count of IPF cases is evident. The 
prognosis for patients with IPF is poor, with a median survival of 3–5 years if 
untreated [1]. IPF generally affects adults over 50 years, mainly in their sixth or 
seventh decade, but the earlier onset was noted in familial IPF. According to the 
epidemiological data, the incidence rates in Europe and North America are between 
2.8 and 19 cases per 100,000 people per year [2]. The number of cases older than 
65 years of age is about 400 per 100,000. The IPF has a prevalence of 8.2 cases per 
100,000 and belongs to the rare diseases group [3]. The first IPF manifestation 
is shortness of breath (up to 85% of cases), chronic non-productive cough (up to 
75%), tiredness, loss of appetite, and progressive exertional dyspnea, followed by 
an impaired quality of life [4]. More rarely, it can be an acute exacerbation (AE), 
acute episodes of sudden, rapid worsening of the disease of dyspnea over just a few 
weeks, and a consequent significant increase in mortality risk [5].
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The pathogenesis of IPF is not completely understood. For many years, IPF was 
principally an inflammatory disease, given the increase in inflammatory cells in the 
lungs. Dramatic advances in the understanding of IPF pathogenesis mechanisms 
over the past decade were based on proteomics data. It discovered proteins in 
terms of prognosis, diagnosis, and IPF progression. Today, we think about IPF as 
an epithelial-driven disease. IPF originates from unknown microinjuries result-
ing from recurrent exposures of the lung epithelium to stimuli or predisposition, 
followed by initiation of alveolar epithelial cells (AECs) dysfunction, fibroblast 
recruitment, and proliferation and progression of fibrosis through fibroblast dif-
ferentiation, myofibroblasts proliferation, and accumulation of extracellular matrix 
and remodeling [6].
Usually, pulmonary function tests reveal reduced total lung capacity, low carbon 
monoxide diffusing capacity, and arterial hypoxemia. Although the course of the 
disease is variable, IPF has a poor prognosis, mortality is high, and reported median 
survival is from 2.5 to 5 years from the time of diagnosis [7, 8].
The most frequent cause of death is respiratory failure. Although there is no 
identified cause for the IPF, men are more frequently affected than women. Genetic 
and environmental factors may contribute to the development or worsen the prog-
nosis of IPF. A history of smoking increases the risk of developing IPF. Occupational 
and environmental risk factors for IPF are agricultural exposure, dusts from metal, 
asbestos, wood, chemicals, air pollution, etc. Although IPF is a disease that is limited 
to the lungs, numerous comorbidities have been increasingly recognized in patients 
with IPF, such as cardiovascular, pulmonary hypertension and ischemic heart dis-
ease, gastroesophageal reflux, lung cancer, chronic obstructive pulmonary disease/
pulmonary emphysema, depression, sleep apnea, and diabetes [9].
Diagnosis of IPF is challenging because the initial symptoms are vague, non-
specific, often mild, and may be attributed to advancing age or other diseases. 
Frequently the diagnosis is complex, requiring a multidisciplinary evaluation 
as recommended by international guidelines. The diagnosis of IPF continues to 
be a diagnosis of exclusion of other known causes for pulmonary fibrosis. High-
resolution computed tomography (HRCT) plays a central role in the diagnosis 
of IPF. The presence of the HRCT pattern of usual interstitial pneumonitis is the 
hallmark of IPF diagnosis. In the case of the inconsistent pattern of UIP, signifi-
cant inter-observer variability, surgical lung biopsy is necessary despite possible 
complications: triggering of the pneumothorax, pulmonary collapse, etc. Specific 
combinations of HRCT patterns and histopathology patterns in patients subjected 
to lung tissue sampling (transbronchial lung cryobiopsy or surgical lung biopsy) are 
an important part of the diagnosis.
In summary, the required criteria for diagnosing IPF is the combination of 
exclusion of known causes of ILD and presence of UIP pattern on chest HRCT or 
exclusion of known causes of ILD and specific HRCT/histology combinations. In 
the case of atypical HRCT presentation, lung biopsy is recommended. However, not 
all patients are eligible due to age and comorbidity limits. The average time from the 
symptoms’ onset to the correct diagnosis is approximately 1.5 years [10–12].
Current guidelines also support the use of clinical, radiological, and physiologic 
evaluations to estimate IPF disease severity and predict disease progression [12]. 
These include quality of life questionnaires and quantitation of IPF exacerbation 
frequency; serial measurements of forced vital capacity (FVC), diffusing capac-
ity for the lungs for carbon monoxide (DLCO), and 6-min walk test (6MWT) 
distances; and sequential HRCT scans when indicated. Composite scoring systems 
such as the Composite-Physiologic Index (CPI) and Gender Age Physiology (GAP) 
index, which incorporate demographic and physiological data, may represent more 
accurate prognostic models [13, 14].
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IPF patients usually respond poorly to therapy. The treatment is based on the 
use of antifibrotic drugs (nintedanib or pirfenidone), which slow down the disease 
progression, but they do not significantly improve the survival of these patients. 
Lung transplantation is the only treatment option that increases survival in IPF. 
Early intervention may help improve clinical outcomes [15].
2. Biomarkers
A growing body of knowledge highlights IPF diagnosis, and providing accurate 
prognostic information is difficult using the currently available clinical, radiologi-
cal, and physiologic findings. Furthermore, pulmonary function tests, clinical 
assessments, and imaging are very good for some cases, but not good for others. 
For example, lung biopsy is often not feasible in an elderly population with co-
morbidities, etc. [16].
With the development of new treatments for IPF, it is critical to identify 
patients at an earlier stage of disease and rapidly identify those patients who will 
progress to worse clinical outcomes. That’s why there has been an emergence 
of molecular biomarkers. Compared to today’s diagnostic methods, an optimal 
biomarker for discriminating patients with IPF from healthy subjects or non-IPF 
patients should be less invasive, more rapid, and reproducible, easier to obtain 
from patients.
At the same time, we are the witnesses that non-invasive biomarkers can pro-
vide very important information for the clinical assessment of patients. Although 
considerable advances have been made in the last decade in revealing IPF patho-
genesis, this is not the case with IPF biomarkers. Similar to the previous guidelines, 
current existing guidelines such as 2021 German Respiratory Society (DGP), 2018 
American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese 
Respiratory Society (JRS), American Latin Thoracic Association (ALAT) guidelines 
strongly recommend not to measure any serum biomarker for IPF diagnosis and 
distinguishing IPF from other interstitial lung diseases in patients with newly 
detected ILD of apparently unknown cause who are clinically suspected of having 
IPF. Also, no guidelines on prognostic biomarkers are available [12, 17–20].
Although there is no molecular biomarker in widespread clinical use for IPF, 
advancements in this field have been achieved; a growing body of literatures 
indicates a fascinating field of IPF biomarkers has reported changes in the level of 
various biomarkers in IPF patients, which implies the potential to become a new 
tool for clinical practice of IPF.
IPF biomarkers include:
a. predisposition biomarkers for identification of patients at risk for devel-
oping IPF
b. diagnostic biomarkers for identification of IPF patients and differentiation 
of IPF patients from healthy controls or patients with other ILD or another 
lung disease
c. prognostic biomarkers for staging disease severity, monitoring disease progres-
sion, herald worsening of IPF or the onset of an acute exacerbation or more 
accurate prediction of mortality




e. biomarkers used as a surrogate endpoint in clinical trials helping predict clinical 
benefit based on epidemiologic/therapeutic/pathophysiologic evidence [21–23].
It is very well known that the ideal biomarker should be noninvasive, easily 
measured by a single, readily available test, to have high sensitivity/specificity, to be 
reproducible, accurate, widely available, and cost/effective [24].
Before considering the clinical implementation of the biomarker candidate, it 
must be evaluated critically with respect to key analytical and clinical character-
istics. Criteria to be satisfied for definitive clinical implementation of biomarker 
related to the test such as adequate assays for its measurement, its predictive value 
defined in specific clinical contexts, optimal cut-off(s), and known timing of 
measurement (release kinetics) [25, 26].
Biomarkers should be measured from body fluids or tissues (serum, urine, 
exhaled breath condensates bronchoalveolar lavage fluid (BALF) transbronchial 
biopsy, surgical lung biopsy, etc.) with a recommendation to use easily obtainable 
body fluids or tissues. Although airway biomarkers could be obtained non-inva-
sively via exhaled breath, is simple to collect and unlimited in quantity, most studies 
used bronchoscopy to obtain these biomarkers via BALF [27].
Additionally, incremental marker value should be examined, and the data about 
the effect on patient management and outcome and cost-effectiveness should be 
available. Also, validation across sexes, ages, ethnicities, and disease severity to 
assure generalizability is very welcome.
This chapter will summarize our current knowledge about IPF biomarkers 
associated with alveolar epithelial cell damage and dysfunction, biomarkers related 
to extracellular matrix remodeling and fibroproliferation, as well as biomarkers 
related to immune dysfunction.
3. Markers of alveolar epithelial cell damage and dysfunction
Markers that belong to this group are the most studied biomarkers and offer the 
most convincing data. The increase in serum levels of these markers can be attrib-
uted to an increase in the production of these proteins by regenerating alveolar 
type II cells and/or to an enhanced permeability following the destruction of the 
alveolar-capillary barrier [28].
3.1 Krebs von den Lungen-6 (KL-6) antigen
Krebs von den Lungen-6 (KL-6) antigen is a high molecular weight glycoprotein 
belonging to the group of human transmembrane mucins, expressed on type II 
pneumocytes, bronchial epithelium, as well as in glandular epithelium, including 
breast and pancreatic epithelium [22].
It was originally studied as a potential tumor marker in adenocarcinoma, 
whereas today’s research is mainly based on KL-6 as a diagnostic and prognostic 
biomarker in ILD [22]. It shows marked inter-individual variability in serum levels.
Although few studies have revealed the KL-6 role as a diagnostic marker for IPF 
and found a higher value of KL-6 in patients IPF compared to controls. KL-6 was 
approved in Japan more than twenty years ago as a diagnostic biomarker in ILD [29].
Serum concentrations of KL-6 depend on the polymorphism of the MUC1 gene 
encoding its synthesis, which accounts for the different values in people of different 
ethnicities [29]. For these reasons, validation in the non-Asian population is neces-
sary for this biomarker to be internationally used in patients with IPF [30].
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However, KL-6 has been mostly studied as a prognostic biomarker. KL-6 values 
are predominantly increased in ILD, characterized by damage to AECs and progres-
sive thinning of the interstitium, including IPF. A serum cut-off value of ≥1000 U/
ml is associated with a poorer prognosis of patients with ILD and a higher risk of 
death [30].
KL-6 fluctuations in the follow-up of IPF patients have also been reported to 
be potentially useful in predicting functional disease progression [31]. Few stud-
ies examined the prognostic significance of serial measurements of KL-6 levels in 
IPF. Sokai et al. [32] found that serial measurements of serum KL-6 may provide 
additional prognostic information than physiological parameters in patients with 
IPF. Wakamatsu et al. [33] found that patients with both initial serum KL-6 values 
<1000 U/mL and no serial increase in KL-6 had more favorable prognoses than 
those with serial increases in KL-6 or initial serum KL-6 values ≥1000 U/mL. 
Bennett et al. [34] revealed that higher KL-6 levels in BALF are related to the more 
severe and extended disease.
As previously discussed, the course of IPF varies widely, and some patients 
experiencing acute exacerbations of IPF, but the risk factors contributing to AE 
are unclear. It was noticed that basal values of KL-6 are significantly higher in 
patients who develop AE compared to patients with stable IPF [30]. Qui et al. 
[35], in systematic review and meta-analysis, investigated the risk factors for AE 
in IPF patients. The meta-analysis included seven articles involving 14 risk factors 
for AE in IPF patients, and poor pulmonary function, mechanical procedures, 
higher serum KL-6, and secondary pulmonary hypertension were associated with 
increased risks of AE in IPF patients.
Meta-analysis of 10 studies in IPF found that KL-6 had the strongest association 
with diagnosis of lung fibrosis compared with the three other examined markers 
(SP-D, SP-A, and MMP7) until for prognostic studies (decline in forced vital capac-
ity and/or mortality) in IPF, KL-6 showed significant prognostic value [36].
Recently published systematic review and meta-analysis [37] was evaluated the 
robustness of available evidence for the use of KL-6 measurements in blood to pre-
dict prognosis in IPF patients. Twenty-six studies were included in the systematic 
review, and 14 studies were mainly performed on Asian patients in meta-analysis. 
The meta-analysis found that IPF patients with increased KL-6 concentrations had 
a significantly increased risk of developing AE, but the relation of KL-6 concentra-
tions with mortality was not found.
3.2 Mucin 5B
Secreted mucins are the most abundant glycoprotein component of mucus. 
Secreted mucins (MUC2, MUC5AC, MUC5B, MUC6–8, and MUC19) are secreted 
into the extracellular space [38] MUC5B is among the major best-described, 
secreted gel-forming mucins. The main tissues expression of MUC 5B is; respiratory 
tract, submandibular glands, endocervix. Mucin 5B is one of the main components 
of respiratory secretions, and it participates in defense of the respiratory system 
from infections [39, 40]. However, the accumulation of this gel-forming glyco-
protein further contributes to impaired gas exchange and complicates the clinical 
features of IPF patients [41]. The over-expression of mucin 5B in a study in mice 
showed a negative effect on mucociliary clearance, so inhaled harmful substances 
remain in the airways longer and initiate damage, and consequently tissue repair 
with fibrotic changes [42].
In 2011, a genome-wide linkage study identified a locus on chromosome 11 
that was significantly associated with IPF risk. A common single nucleotide 
Idiopathic Pulmonary Fibrosis
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polymorphism (SNP) (rs35705950) in the promoter of the gene encoding for Mucin 
5B (MUC5B) is associated with an increased risk for IPF [43, 44]. Meta-analysis 
of Zhu et al. [45] revealed a strong association between the MUC5B promoter 
rs35705950 polymorphism and the risk of IPF, and confirmed that the minor T 
allele is significantly associated with an increased risk of IPF compared.
The same polymorphism has been associated with higher concentrations of 
MUC5B and its distribution, predominantly in the epithelial cells of small airways 
[46]. Mutations in this gene are not the only cause of increased mucin expres-
sion. Recent data indicate that increased DNA methylation is also associated with 
increased MUC5B expression [47]. This association has not been clarified yet and is 
certainly a topic for future research.
It was also shown that mucin 5B could be a good prognostic marker. Namely, 
the mutation in the promoter region of the MUC5B gene is associated with a lower 
risk of lethal outcome [48]. It has not yet been found how the same mutation leads 
simultaneously to an increased risk of disease. Yet, it is associated with a better 
prognosis and a higher degree of survival.
3.3 Oncomarkers
Certain similarities between IPF and lung cancer have already been identified. 
Both diseases primarily affect the lower parts of the lung lobes; risk factors such 
as smoking, exposure to harmful substances in the living and work environment, 
viral infections, and others are also common. There are also certain similarities in 
pathogenetic mechanisms, such as genetic and epigenetic changes, dysfunctions at 
the molecular and cellular levels, and activation of certain signaling pathways [49]. 
All the above indicates the possibility of using certain tumor markers in IPF when 
assessing the severity of the disease and predicting the outcome [50].
Carbohydrate antigen 19-9 (CA 19-9) is a marker of epithelial damage, widely 
used as a serum tumor marker of carcinoma of the pancreas and digestive system 
[51]. An increase in the concentration of this marker has been observed in patients 
with IPF, but the significance of determining it is still speculative.
Another widely used tumor marker that indicates the severity of the disease in 
IPF is CA 15-3. This glycoprotein, or the most significant tumor marker of breast 
cancer, is elevated in patients with pulmonary fibrosis. It is useful in predicting 
the severity of the disease, and after lung transplantation, there is a decrease in its 
concentration [50].
Carcinoembryonic antigen (CEA), a glycoprotein used as a serum tumor marker 
of colon, rectum, stomach, pancreas, lung, and breast cancer, also stands out as 
a useful marker in IPF [52]. The values of this analyte are elevated in IPF and are 
associated with the severity of the disease [52].
Yin and Lloyd [53] recently identified MUC16 as a transmembrane mucin 
corresponding to the CA125 antigen, long known as a marker for ovarian cancer. 
Recently, CA125 was identified as a serum biomarker for disease progression and 
death in IPF patients.
In the analysis from the PROFILE study, examining 123 serum proteins in IPF 
patients, Maher et al. [54] singled out primarily CA19-9, CA125, and SP-D as three 
markers with the greatest potential for routine use in clinical practice. Although these 
three biomarkers are all secreted in small amounts by the pulmonary epithelium 
in states of health, SP-D being secreted by alveolar type 2 cells and CA19-9 and 
CA-125 by the bronchial epithelium, they are secreted abundantly by the metaplastic 
epithelium of IPF patients. Mahler et al. [54] indicate that the potential of these 
parameters is reflected precisely in their ability to distinguish patients from healthy 
people (SP-D) reliably, predict disease progression (CA 19-9), and dynamically reflect 
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disease progression and overall mortality (CA 125) [54]. By examining the concen-
trations of CA19-9 in the final stage of IPF, Balestro et al. [55] got results consistent 
with previous research. Namely, most patients at this stage of the disease had CA19-9 
values above the threshold (37kU/L). As confirmed by the results of several studies on 
different populations, CA19-9 is a reliable marker of disease progression [50, 54, 55].
The direct mechanisms of the increase in the concentration of tumor markers 
in idiopathic pulmonary fibrosis remain unclear. Nevertheless, research results 
are consistent in that these already widely used markers are useful in assessing the 
severity and progression of IPF [49, 50]. The great potential of these molecules is 
reflected, among other things, in the fact that they are already in routine use, as 
well as that there are commercial tests for their determination, unlike many of the 
aforementioned potential markers of the IPF.
3.4 Surfactant proteins
Surfactant proteins are lipoprotein complexes synthesized and then secreted 
exclusively by alveolar epithelial cells, bronchial epithelial cells, as well as Clara cells 
[56]. They are encoded by SFTPA, SFTPB, SFTPC, and SFTPD genes [57]. Their 
role is to reduce surface tension in the alveoli and prevent their collapse [58].
Surfactant proteins themselves, as well as mutations in the genes encoding these 
proteins, have been described as potential biomarkers in IPF [22]. Mutations in the 
genes for surfactant proteins (SP) C and A2 have been associated with the develop-
ment of oxidative stress and damage to the endoplasmic reticulum, but an addi-
tional profibrotic stimulus is necessary to induce the development of pulmonary 
fibrosis [59–61].
However, SP-A and SP-D are the most studied surfactants in IPF, as well as 
surfactants studied for the longest time. The mechanisms by which SP-A and SP-D 
from pneumocytes enter the circulation are hyperplasia of AECs and thus increased 
synthesis of these proteins, and loss of AEC integrity i.e., increased permeability of 
the basement membrane of the pulmonary epithelium to the interstitium [58].
In the serum of patients with IPF, there was a significant increase in the con-
centration of SP-A and D, while in contrast, their concentration in BAL was lower 
compared to healthy, control subjects [58]. In addition, an increase in SP-D has 
been found in patients with acute exacerbations of the disease [62]. This surfactant 
protein may be useful in detecting patients who are more prone to disease progres-
sion and poorer outcomes [54]. There is evidence that SP-D is a biomarker that can 
be used for differential diagnosis of interstitial lung disease, as its level is higher in 
IPF than in other ILDs [63].
Wang et al. [64], in a meta-analysis of 21 articles, evaluated the use of serum 
SP-A and SP-D for differential diagnosis and prognosis of IPF. Serum SP-A levels 
were significantly higher in patients with IPF than in patients with non-IPF ILD. In 
the AE of IPF, serum SP-A/D was higher than those in the stable stage.
Studies, therefore, show that these proteins, as well as KL-6 and matrix metal-
loproteinase-7 (MMP-7), are predictive markers; however, in some studies, only 
SP-A and SP-D are independent predictors of mortality [65]. In addition, SP-D 
has proved to be a more sensitive marker than SP-A, with a sensitivity of 77% 
(SP-A sensitivity is 33%). However, these markers are not specific to IPF, but their 
increase is also observed in other interstitial lung diseases. Also, a study conducted 
in South Korea has shown that the application of these biomarkers in IPF, combined 
with clinical parameters, does not significantly contribute to the assessment of 
outcome compared to the application of clinical parameters alone. However, if KL-6 




Compared with SP-A and SP-D in the serum of patients with IPF, the data 
for SP-B are limited. SP-B is a component of pulmonary surfactant, produced 
by alveolar epithelial cells, which is synthesized as a preproprotein [66]. The 
maturation process of this protein involves primarily the removal of the signal 
peptide, followed by the glycosylation of the C-terminal region, and finally, the 
cleavage of the N- and C-terminal propeptides [67]. Mature surfactant protein B 
is hydrophobic and strongly associated with phospholipids rich in surfactants. At 
the same time, its precursors, proSP-B, and C-proSP-B are more hydrophilic so that 
they can be found in the supernatant of bronchoalveolar lavage [68]. In healthy 
subjects, concentrations of both mature and SP-B precursors are almost undetect-
able in serum [69]. The study of Khan et al. [68] has been studied SP-B precursor, 
C-pro-SP-B, as a new biomarker in serum of patients with different chronic lung 
diseases, including ILDs. The highest C-proSP-B levels were detected in the serum 
IPF patients. In a multivariate analysis, C-proSP-B levels were able to discriminate 
IPF patients from patients with all other pulmonary diseases (p < 0.0001). SP-B 
pre-proteins might serve as a biomarker in pulmonary diseases with alveolar or 
interstitial damage in IPF.
3.5 Clara cell secretory protein (CC16)
Clara cells are exocrine bronchiolar cells with several different physiological 
functions, including a protective and regenerative role, as well as a role in maintain-
ing pulmonary homeostasis [70]. These cells’ protective and regulatory function 
is achieved through the secretion of various surfactants, glycosaminoglycans, 
enzymes, and other proteins [70]. In addition, these cells are involved in the 
biotransformation of many harmful substances that enter the lungs through the 
inhaled air [71].
CC16 is a 16 kDa homodimeric secretory protein of Clara cells with anti-inflam-
matory and antioxidant properties and has been studied as a potential therapeutic 
agent in various lung diseases [70]. It is encoded by the SCGB1A1 gene. Low serum 
CC16 values are associated with decreased lung function in children, accelerated 
decline in lung function in adults, and an increased risk of death, primarily in lung 
cancer [72].
In contrast, significantly high values of CC16 have been observed in the serum 
and bronchoalveolar lavage of patients with IPF [72]. Also, CC16 values are high 
in other interstitial lung diseases, such as sarcoidosis, although the values are 
significantly higher in IPF [72]. It is assumed that the activation of Clara cells after 
the alveolar epithelium damage leads to elevated serum concentrations of CC16. 
However, the exact role of CC16 in the alveolar repair process has not been thor-
oughly tested [70]. Although CC16 is a potential biomarker in various lung diseases, 
further studies are needed since CC16 values do not correlate with disease severity; 
there are no reference values, nor can it be used independently in diagnostics since 
it is a non-specific marker [70].
3.6 Telomeres
Telomeres are repetitive nucleotide sequences at the ends of chromosomes, 
whose role is to protect chromosomes from degradation [73]. As DNA polymerase 
cannot completely replicate the DNA strand, wherein a sequence of about 50 
nucleotides is lost during each replication, the importance of telomeres is reflected 
in the fact that during replication, these non-coding parts of chromosomes are 
lost. The loss of telomere parts is compensated by the telomerase enzyme, which 
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incorporates guanine-rich sequences at the ends of chromosomes during cell repli-
cation. However telomeres become shorter during repeated replications, resulting 
in cell aging and apoptosis [74].
It has been found that approximately one-third of patients with familial IPF 
have shortened telomeres, and/or mutations in the gene encoding telomerases [75]. 
When examining telomere length in peripheral blood leukocytes in patients with 
IPF, it was found that 40% of patients with familial IPF and a quarter of patients 
with sporadic IPF have shortened telomeres, below the 10th percentile [76]. In a 
2014 cohort study involving over three hundred patients with IPF, it was found 
that telomere length in peripheral blood leukocytes was an independent predictor 
of mortality [77]. It was also found that telomere shortening in peripheral blood 
leukocytes as a surrogate marker for telomere mutations, so telomere length in 
peripheral blood may be examined in the family of a carrier of these mutations, 
instead of carrying out genetic analysis, which would indicate a risk factor for 
familial IPF [78].
3.7 αvβ6 integrin
Integrins are receptors found on the surface of cells, and they have a role in 
their binding to the extracellular matrix, in the interconnection of cells, and their 
migration, proliferation, and innate immune response [79]. Structurally they are 
heterodimers, made of different α and β subunits, and the αvβ6 integrin itself 
consists of αv and β6 subunits. The β6 subunit is expressed only in epithelial cells, 
so the whole integrin is present only. This integrin is extremely important for the 
pathogenesis of IPF, as it can activate transforming growth factor beta (TGF-β), 
which is involved in the interaction of lung epithelial cells and fibroblasts [80]. In 
patients with IPF, higher concentrations of this integrin have been found in lung 
tissue [81]. Also, higher concentrations of integrin are associated with a poorer 
prognosis [82].
4. Markers of fibrogenesis and extracellular matrix remodeling
4.1 Matrix metalloproteinases (MMP)
Matrix metalloproteinases (MMP) are zinc-dependent proteases, which 
degrade the extracellular matrix. They can modulate the proliferation, migra-
tion, and apoptosis of smooth muscle cells, endothelial cells, and some types of 
immune system cells. So far, 23 members of this family have been discovered, 
encoded by 24 genes, where two genes serve to encode the same matrix metal-
loproteinase - MMP-23 [83]. Under physiological conditions, the activity of these 
enzymes, collectively called matrixins, is regulated at the level of transcription, 
activation of their inactive zymogen precursors, interaction with extracel-
lular matrix components, and finally inhibition by endogenous inhibitors [84]. 
Matrixins are divided into seven categories: collagenases, gelatinases, strome-
lysins, membrane-type MMP, matrilysins, metalloelastases, and other types of 
matrixins [85].
Although MMPs are expected to prevent fibrotic changes due to their many 
functions and role in ECM degradation, these enzymes can have both a profibrotic 
and an antifibrotic role [85]. More details on members of the MMP-7 and MMP-1 





This metalloproteinase is expressed in alveolar epithelial cells, phagocytes, and 
fibrocytes. An increase in MMP-7 levels has been observed in patients with IPF, and 
this enzyme has been confirmed as a biomarker of IPF [86]. The expression of this 
matrixin in the lung epithelium in IPF is further increased by osteopontin, a marker 
that will be discussed later [87]. Two SNPs have been identified in the promoter 
of the MMP-7 gene, which causes increased transcription, and are associated with 
the development of idiopathic pulmonary fibrosis [88]. In addition, as an enzyme 
that effectively removes tissue pathway factor inhibitor (TPFI), MMP-7 creates a 
procoagulant environment in the alveolar space, which has been observed in many 
fibrotic diseases, including IPF. Although this enzyme is also involved in the regen-
eration of lung epithelium after damage, in studies in mice lacking the MMP-7 gene, 
it was not possible to induce pulmonary fibrosis (PF) with bleomycin, suggesting 
that this metalloproteinase nevertheless promotes the development of PF [89]. This 
fact singles out MMP-7 as a potential new therapeutic target.
White et al. study tested the differentiation of IPF from a heterogeneous com-
parator group that included various other ILDs [63]. In another study, the serum 
MMP7 levels of IPF patients were compared to a group of patients with other ILD. 
Serum MMP7 values had a median sensitivity, specificity, accuracy, and diagnostic 
odds ratio of 71.7, 64.4, 68.4, and 4.7%, respectively [90]. MMP7 indicates a correct 
IPF diagnosis in more than half of the patients, suggesting an incorrect classifica-
tion in about one-third of patients. Based on these data, the diagnostic value of 
these serum biomarkers is currently considered insufficient to support clinical 
use [17].
The Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial that assessed 
potential prognostic capabilities of few biomarkers showed that MMP-7 is higher 
than healthy controls. Baseline MMP-7 levels were good predictors of worsening 
and could predict changes in FVC as early as month 4. MMP-7 shows the potential 
to be a reliable predictor of lung function decline and disease progression [91].
Despite the promising data regarding MMP-7 as a prognostic biomarker of IPF, 
it is not included in clinical practice due to the lack of reproducible, uniform cut-off 
values in different studies. There are major discrepancies between different studies 
about collection matrices; for example, EDTA collection tubes suppress MMP activ-
ity while PBMC layers are sometimes [10% of cases) contaminated by neutrophils, 
therefore significantly affecting predictive cut-off thresholds [92].
4.1.2 MMP-1 (collagenase type I)
This type of matrixin degrades the extracellular matrix collagen; it is not 
expressed in healthy tissue but during physiological and pathophysiological pro-
cesses [87]. Along with MMP-7, MMP-1 is the most studied matrixin in IPF. The 
combination of these two matrixins in the diagnosis of IPF has a positive predictive 
value of up to 91% (for concentrations of MMP-7 > 2.6 ng/mL and MMP-1 > 8.9 ng/ 
mL). Additionally, elevated values of these two MMPs can reliably distinguish IPF 
from other ILDs [86].
4.2 Osteopontin
Osteopontin (OPN) is an acidic phosphorylated glycoprotein secreted by various 
cells, including osteoclasts, activated T-lymphocytes, and activated macrophages [93]. 
Osteopontin is a multifunctional cytokine involved in various biological processes, 
including cell adhesion, chemotaxis, and reparative processes [87]. In this regard, the 
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biological role of osteopontin in the pathogenesis of cardiovascular diseases, diabetes, 
glomerulonephritis, and several types of cancer is suggested [93, 94].
The function of osteopontin in the occurrence of pulmonary fibrosis was tested 
in experimental mouse models, where the role in promoting the migration, adhe-
sion, and proliferation of fibroblasts in the bleomycin-induced pulmonary fibrosis 
was demonstrated [93, 94]. In addition, analysis of lung biopsy samples of patients 
with IPF showed that osteopontin is a cytokine with the highest expression [93].
Osteopontin serum values are significantly higher in AE of IPF, compared to 
values in stable IPF, which is associated with a poorer prognosis [87, 95]. Although 
OPN is increased in serum and BALF of IPF patients [96], it is not specific in dif-
ferentiating IPF from other ILDs [93].
The studies did not show the correlation between OPN concentration and 
SP-A and KL-6 concentrations, which can be explained by the different origins of 
these markers. Serum values of KL-6 and SP-A better reflect a later phase of the 
fibrosis process, i.e., the remodeling phase [93]. Although OPN values are highest in 
patients with IPF, no significant differences were observed compared to the values 
in patients with other ILD subtypes, indicating the limited use of this biomarker in 
differential diagnosis [94].
4.3 Periostin
Periostin is an extracellular matrix protein from the fascicline family, and it is 
involved in the pathogenesis of various diseases accompanied by increased levels of 
inflammation and fibrosis [97]. Studies have shown that periostin is a protein that 
is highly expressed in the lungs of patients with IPF [97, 98]. The highest level of 
periostin expression in the lungs is in fibroblasts, in the areas of active fibrosis [97]. 
Stimulation of periostin synthesis in fibroblasts is influenced by various factors, 
including TGF-β and IL-4/IL-13 [98]. Experimental mouse models have shown 
that suppression of the periostin gene or administration of neutralizing antibodies 
protects to a large extent against bleomycin-induced pulmonary fibrosis [99]. Also, 
periostin acts in cooperation with inflammatory cytokines, such as TNF-α, by acti-
vating NF-κB, which is accompanied by the production of inflammatory cytokines 
and chemokines, leading further to the development of pulmonary fibrosis [97].
All this indicates the importance of the biological role of periostin in the 
pathogenesis of PF. However, elevated serum levels of periostin are also observed 
in other inflammatory diseases, which is why there is a need to develop a test that 
will enable greater diagnostic specificity [98]. There is a test designed to determine 
specifically periostin monomers, which is a better diagnostic marker compared 
to total periostin [98]. In addition, both total and monomeric periostin are better 
predictive markers of short-term deterioration of IPF compared to conventional 
markers KL-6, SP-D, and LDH [98]. The potential role of periostin in the treatment 
of patients with IPF should also be noted since experimental mouse models have 
shown that suppression of periostin expression or administration of neutralizing 
antibodies may result in improvement in the fibroproliferative phase [99].
4.4 Lysyl oxidase 2-like protein (LOXL2)
Lysyl oxidase (LOX) and lysyl oxidase-like proteins (LOXL) represent a group 
of enzymes with important roles in extracellular matrix remodeling, including 
covalent binding of elastin and collagen [100]. The LOXL proteins promote collagen 
accumulation and deposition, participating in ECM stabilization. In addition to 
the enzymatic function, LOX also has a function in regulating the transcription of 
elastin and collagen III genes [101].
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Four LOX isoenzymes (LOX1-LOX4) encoded by genes located on different 
chromosomes have been identified [101]. Changes in LOX expression, i.e., increased 
LOX activity, have been associated with the mechanisms of fibrotic changes in cer-
tain lung, liver, and kidney diseases [101]. Increased LOX expression was observed 
in experimental mouse models in bleomycin-induced pulmonary fibrosis [101].
Also, elevated serum concentrations of LOXL2 in patients with IPF have been 
associated with a higher risk of disease progression but cannot be correlated with 
disease severity [101, 102]. Given its role in the pathogenesis of pulmonary fibrosis, 
the applicability of LOXL2 as a potential therapeutic target was examined. However, 
the study of the use of a monoclonal anti-LOXL2 antibody (simtuzumab) in the 
treatment of patients with IPF was discontinued in the second phase of the clinical 
trials due to the lack of efficiency [101]. One of the potential reasons for failure is 
the impossibility of adequate penetration into the lung tissue, but there were not 
enough data for a complete evaluation [101]. In any case, further testing of the diag-
nostic, predictive and prognostic value of LOXL2 as a biomarker in IPF is necessary.
4.5 Insulin-like growth factors and their binding proteins
IGFs are hormones or growth factors primarily synthesized in the liver. For the 
most part, they are bound to some of their binding proteins (IGF-BP), which mod-
ulate their effects and bioavailability [103]. The IGF binding protein family consists 
of six members, which also originate primarily from the liver. IGF and IGF-BP are 
synthesized locally in many tissues to achieve their autocrine and paracrine effects, 
respectively [104].
Studies have shown a significant increase in circulating concentrations of these 
binding proteins in newly diagnosed IPF patients. In contrast, in those patients who 
started using antifibrotic drugs, lower levels of GFBP-2 were found than in patients 
who do not receive this type of therapy [105]. IGFBP-2 values do not return to the 
levels of healthy subjects, even with the use of antifibrotic therapy [105].
As IGFs are very strong growth factors, their significant increase in the process 
of fibrosis, and even lung fibrosis, is expected. However, Guiot et al. [105] found 
a decrease in the concentration of these analytes in the serum of IPF patients. 
These surprising results can be explained in several ways. It is possible that IGF-BP, 
by binding to the extracellular matrix in the lungs with fibrotic changes, locally 
releases IGF and thus enables its effects in such an environment. On the other hand, 
an increase in the concentration of binding proteins to insulin-like growth factors 
means that these factors bind to a greater extent, thus reducing their effectiveness, 
which can also have a protective role in IPF [106–108].
4.6 Fibulin 1
Fibulin 1 (Fbln1) is a secretory glycoprotein with a significant role in embry-
onic morphogenesis and alveolar septal formation [109]. Four isoforms of this 
protein (Fbln1a/b/c/d) have been isolated, differing from each other in C-terminal 
sequences [110]. However, the identification of individual variants is difficult due 
to the unavailability of antibodies specific to certain isoforms [111]. Fbln1 has 
an important role in tissue repair and has been associated with several different 
respiratory diseases [111]. The importance of the Fbln1c form in the pathogenesis of 
various respiratory diseases is especially emphasized, which is achieved through the 
stimulation of fibroblast proliferation and remodeling of the extracellular matrix 
[110, 111]. Experimental mouse models have shown that the inhibition of Fbln1c 
expression reduces the proliferation of smooth muscle cells and fibroblasts and 
collagen deposition around the small airways [111]. In addition, mouse models have 
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shown a significant role of Fbln1c in chronic inflammation, where the inhibition 
of Fbln1c expression reduces the influx of inflammatory cells into the bronchoal-
veolar lavage and the synthesis of cytokines and chemokines in the lungs [111]. 
Accordingly, Fbln1 is mentioned as a potential biomarker and therapeutic target in 
respiratory and other diseases involving inflammation and remodeling [111].
Elevated values of Fbln1 in the serum and lungs of patients with IPF compared 
to healthy subjects suggest a role of Fbln1 in the pathogenesis of this disease [109]. 
High values of Fbln1 in the lungs are a consequence of increased production in 
smooth muscle cells and fibroblasts; apart from that, under the influence of TGF-β, 
exogenously synthesized Fbln1 is incorporated into the extracellular matrix [111]. 
The high serum concentration of Fbln1 correlates with decreased lung function 
and is associated with acute exacerbation of the disease [109, 112]. Fbln1 values are 
higher in patients with IPF compared to other ILDs. Still, they are in correlation 
with pulmonary function in other types of disease, suggesting that Fbln1 may be a 
predictive marker of disease progression in other ILDs, such as idiopathic nonspe-
cific pneumonia [109].
4.7 Neoepitopes
Excessive deposition of the extracellular matrix is critical to the pathogenesis of 
IPF. Collagen is the main component of the extracellular matrix, whose synthesis 
and degradation take place in a balanced way in healthy lungs, while in IPF, this 
balance is disturbed [113, 114]. During synthesis, the procollagen is cleaved, and 
during the degradation of collagen molecules, MMPs cut parts of this molecule, 
which reveals different neoepitopes in all these processes [115].
Peptides formed during synthesis and newly formed neoepitopes are released 
into the circulation and detected in the blood. Studies have shown that serum 
concentrations of neoepitopes of collagen synthesis PRO-C3 and PRO-C6 (collagen 
type 3 and type 6) are higher in patients with IPF compared to healthy subjects of 
the same age. Their elevated concentration is associated with IPF progression [115]. 
The concentration of collagen degradation markers (C1M, C3M, C6M, and CRPM) 
is also elevated in IPF. Longitudinal changes in serum concentrations of these neo-
epitopes follow the progression of fibrosis and can predict mortality in individuals 
with IPF in three months [116]. Biomarkers of collagen synthesis and degradation 
have the potential to improve clinical trials in IPF, prognostic evaluation, and make 
decisions on therapy [115].
4.8 Heat shock protein 47 (HSP47)
HSP47 is a protein necessary for the synthesis and secretion of collagen mol-
ecules. Increased expression of HSP40 is closely related to excessive production and 
accumulation of collagen, so these data indicate a significant role of this molecule in 
fibrotic processes and its correlation with the activity of such diseases. It has been 
shown that a significant increase in the concentration of HSP47 occurs during the 
acute exacerbation of the disease, compared to the stable form of IPF. Additionally, 
this biomarker has been found to be superior to better known and studied markers 
of pulmonary fibrosis, such as KL-6 and SP-A and D [117]. It was assumed that, as 
HSP47 concentrations in the exacerbation phase of the disease are higher than dur-
ing stable disease, this distinction would also exist between patients with a stable 
form of the disease and healthy subjects. However, these assumptions have been 
refuted in the research conducted [117, 118].
The precise role of HSP47 in the pathogenesis of IPF has not been determined, 
but this molecule is likely responsible for the additional effect of pirfenidone in the 
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inhibition of fibrotic processes. In addition to direct suppression of type I collagen 
expression, it is possible that pirfenidone partially achieves its anti-fibrotic effect by 
suppressing the expression of HSP47 depending on TGF-β1 [119].
4.9 Circulating fibroblasts and fibrocytes
The lungs are characteristic of IPF patients in the regions of the so-called 
fibroblast foci, where ECM production is most active. In these foci, the predomi-
nant cells are myofibroblasts, where under the effect of various cell mediators, 
the proliferation of these cells takes place, with the inhibition of their apoptosis 
[120]. Myofibroblasts are cells that phenotypically correspond to the stage between 
fibroblasts and smooth muscle cells [121].
There are two hypotheses on the origin of myofibroblasts: traditional – that they 
are formed from fibroblasts after their activation by inflammatory stimuli and more 
recent – that they are formed by differentiation of alveolar epithelial cells [122].
Fibrocytes are cells originating from the monocytic lineage. In case of tissue 
damage, migrate to the site of damage attracted by chemotactic factors and then 
differentiate into fibroblast-like cells. They are present in the circulation and can 
produce ECM. Fibrocytes express different markers, and these are primarily CD45 
leukocyte markers and type I collagen. During its differentiation, it has been found 
that CD45 expression gradually decreases while type I collagen expression remains 
unchanged. It has also been found that their differentiation is accelerated under the 
effect of TGF- β [123]. Although they have a protective role in the process of tissue 
remodeling and damage repair, it is considered that fibrocytes are involved in the 
progression of pulmonary fibrosis. Studies show that in the blood of IPF patients, an 
increased number of circulating fibrocytes is associated with a poor disease outcome 
[124, 125]. It has been found that, compared to healthy subjects, in patients with IPF, 
there is a significantly higher number of circulating fibrocytes, identified precisely 
as CD45+, collagen type I+ cells. In addition, in patients with AE of the disease, 
these cells are present in ten times greater numbers than in the case with a stable 
state [125].
5. Markers of immune system dysfunction and inflammation
Although IPF is primarily not an inflammatory disorder, inflammatory and 
immune-mediated pathways are activated in IPF patient’s lungs.
5.1 CC chemokine ligand 18 (CCL18)
CC chemokine ligand 18 (CCL18) is a protein secreted by myeloid lineage  
cells: monocytes, macrophages, and dendritic cells. In patients with idiopathic 
pulmonary fibrosis, alveolar macrophages produce large amounts of CCL18  
[126, 127]. Th2 cytokines lead to alternative activation of alveolar macro-
phages, which thus activated have a role in tissue and fibrosis healing [128, 129]. 
Alternatively, activated macrophages produce CCL18, which leads to increased 
collagen production by pulmonary fibroblasts, and collagen then stimulates alveolar 
macrophages to produce CCL18 by a positive feedback loop. In this way, the process 
of fibrosis is continuously maintained [126].
Increased serum concentrations of CCL18 in IPF are negatively correlated with 
pulmonary function tests and associated with disease progression [126, 127]. In 
a prospective study of 72 patients, significantly higher mortality was observed in 
the group of patients with a CCL 18 concentration above 150 ng/mL [130]. It was 
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also found that pirfenidone used in the treatment of IPF significantly reduces the 
expression of CCL18 in macrophages [130].
Data obtained from meta-analysis Elhai et al. showed that CCL18 has a signifi-
cant prognostic value [36]. Based on previous research, it can be concluded that 
CCL18 is a good prognostic marker in IPF.
In a posthoc analysis of phase 3 ASCEND and CAPACITY trials [131], concen-
trations of IPF biomarkers in IPF patients who received pirfenidone 2403 mg/day or 
placebo were investigated, and their associations with changes in FVC and disease 
progression over one year. CCL18 was consistently prognostic for absolute change in 
percentage of FVC% and was the most consistent predictor of disease progression 
across IPF cohorts.
5.2 CC chemokine ligand 2 (CCL2)
CC chemokine ligand 2 (CCL2) is one of the chemokines involved in the 
recruitment of mononuclear phagocytes, thereby promoting inflammation and the 
development of tissue fibrosis [132]. Additionally, the recruitment of fibrocytes 
into the lungs most likely occurs because of interactions between chemokine ligands 
(including CCL-2) and their receptors [133]. More than 20 years ago, it was estab-
lished that significantly higher serum concentrations of this chemoattractant are 
present in patients with idiopathic pulmonary fibrosis [134]. A recently published 
paper, which focused on examining the prognostic potential of various chemokines, 
found significantly higher concentrations of CCL-2 in patients with both acute 
exacerbations of IPF and a stable form of the disease, compared to a control group 
of subjects [135]. The same study concluded that CCL2 levels, among other chemo-
kines, showed neither correlation with lung function nor patient survival [135].
5.3 CXC chemokine 13 (CXCL13)
CXC chemokine 13 (CXCL13) is a protein secreted by dendritic cells and the 
main mediator in attracting B lymphocytes to inflammatory lesions. Antigen-
stimulated B lymphocytes undergo a process of gradual maturation, so these cells, 
as well as altered, differentiated B lymphocytes, are present in patients with IPF 
[136]. Increased CXCL13 mRNA has been isolated in the lungs of patients with IPF 
compared to control subjects, and serum levels of CXCL13 were increased in patients 
with IPF compared to control subjects. Elevated CXCL13 protein levels are associated 
with increased mortality in patients with IPF. The highest levels of CXCL13 were 
found in IPF patients with acute exacerbations or pulmonary hypertension [137].
5.4 Toll-like receptor 3
The toll-like receptor is a transmembrane glycoprotein receptor expressed 
predominantly endosomal. Recent studies show an association between Toll-like 
receptors and aberrant fibrogenesis characteristic of idiopathic pulmonary fibrosis 
[138]. These receptors recognize molecular patterns that can be potentially danger-
ous and promote adequate immune response [138]. The Toll-like receptor 3 L412F 
polymorphism is associated with defective TLR3 activation, which causes mortal-
ity in IPF [139]. The association of this mutation with accelerated decline in lung 
function and consequent early death has been proven. This information can be 
critical in identifying patients with a rapidly progressive phenotype [140]. Toll-like 
receptor 3 belongs to the group of receptors that have a significant role in innate 
immunity. It mediates the innate immune response to tissue injury or infection 
by inducing NF-κB activation and type 1 interferon production [141]. Toll-like 
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receptors recognize patterns from bacterial, viral, protozoal, and fungal pathogens, 
which are most important for their survival [141]. The Toll-like receptor 3 is a 
receptor that recognizes viral double-stranded RNA (dsRNA) and regulates the pro-
inflammatory response and IFN-1 production [142]. In studies on fibroblasts in IPF, 
the unregulated proliferation of primary fibroblasts was observed and decreased 
production of IFN-β mediated by TLR3 receptors [139]. Activation of TLR3 recep-
tors in primary fibroblasts has an antifibrotic effect and leads to a decrease in 
TGF-β production, increased collagen production, and increased metalloproteinase 
activity [143, 144].
The TLR signaling pathway during the reactive response to viruses acts as a 
blocker of fibroproliferation, so TLR3 signaling deficiency can cause an inadequate 
lung response to viral pathogens and expose them to chronic cycles of damage and 
repair considered the basis of IPF pathology [144].
5.5 Toll-interactin protein (TOLLIP)
Toll-interactin protein (TOLLIP) is a protein whose expression in the lungs has 
been observed in type II alveolar cells, macrophages, and basal cells. This protein 
has a role in important signaling pathways associated with lung diseases, including 
IL-1β, IL-13, TLR, and TGF-β [145].
It has been found that the rs111521887 and rs5743894 gene variants located in 
TOLLIP introns are associated with 40–50% reduced TOLLIP gene expression in 
the lungs and susceptibility to IPF [146]. Interestingly, the rs5743890_G allele is 
related to increased mortality in IPF, although it is associated with decreased IPF 
susceptibility, which suggests that the genetic basis is related to different clinical 
outcomes [39]. This indicates the heterogeneity and complexity of the pathogen-
esis of IPF [146]. TOLLIP is an important regulator of innate immune responses 
mediated by Toll-like receptors and the TGF-β1 signaling pathway through TGF-β1 
receptor degradation [92]. It antagonizes the TGF-β signaling pathway by degrad-
ing the TGF-β1 receptor [147]. This TLR inhibitory protein is potentially useful for 
detecting various responses to the treatment of IPF in different genotypes [148].
Decreased TOLLIP expression increases proinflammatory cytokines IL-6 and 
TNF production in macrophages after TLR stimulation [149]. These data suggest 
that TOLLIP expression may be protective by reducing the proinflammatory and 
profibrotic cascade [144].
5.6 Defensins
Defensins are small antimicrobial peptides mainly secreted by neutrophils and 
epithelial cells, which affect some gram-positive and gram-negative bacteria, as 
well as viruses [92]. Comparative analysis of gene expression from blood and lung 
tissue samples of patients with stable IPF and those with acute exacerbation of IPF 
revealed increased gene expression for alpha-defensins 3 and 4 in IPF with acute 
disease exacerbation [150].
Alpha-defensins are activated by MMP7, whose gene expression is also increased 
in the lungs of patients with IPF [22]. It has been found that serum levels of alpha 
defensin are higher in patients with IPF than in healthy subjects and are associated 
with the deterioration of the disease [150, 151].
5.7 S100A4
S100 calcium-binding protein A4 (S100A4, fibroblast-specific protein-1) 
belongs to the S100 family containing calcium-binding motifs. S100A4 promotes 
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lung fibrosis via proliferation and activation of fibroblasts and promotes the transi-
tion of fibroblasts to myofibroblasts [152].
Akiyama et al. [153] have shown the clinical significance of serum S100A4 in IPF 
patients. They revealed an independent association of higher S100A4 levels with a 
higher disease progression rate and a higher mortality rate, suggesting that S100A4 
may be promising in the prognosis and management of IPF. The presence of higher 
levels of S100A4 in the serum of participants with IPF was linked with a signifi-
cantly lower progression-free survival and higher 2-year mortality.
5.8 S100A8/A9
S100A8/A9 belongs to the S100 family of calcium-binding proteins derived 
from neutrophils and monocytes, which modulate the immune response [154]. In 
the pathogenesis of pulmonary fibrosis, the role of these proteins is based on the 
proliferation of fibroblasts, the influence on their differentiation, and the increase 
in collagen production by mentioned cells [155]. Concentrations of S100A8 and 
A9 are, as recent research results show, significantly higher in patients with acute 
disease exacerbation than in healthy patients, as well as in patients with confirmed 
IPF without acute exacerbation [156]. Patients with higher concentrations of these 
two biomarkers had a significantly poorer three-month survival rate, so S100A8 and 
S100A9 proved to be significant prognostic markers [156].
5.9 S100A12
S100A12 is a member of the S100 family of calcium-binding proteins that has 
a significant role in regulating inflammatory processes and immune response. Its 
proinflammatory activity includes chemotaxis and activation of the intracellular 
signaling cascade, leading to cytokine and oxidative stress production [157]. In a 
study with a relatively large number of patients with IPF, serum concentrations of 
S100A12 in IPF were high and correlated with poor disease prognosis [158].
5.10 Anti-heat shock protein-72 antibodies (AHSP-72)
HSP production is regulated by various stress effects on cells, as well as their 
damage. They are located on the cell surface and have a role in transmitting infor-
mation and modulation of the immune response [159]. Various autoantibodies to 
HSP have been found in patients with autoimmune diseases. What singled out HSP 
and autoantibodies to these proteins as potential biomarkers in IPF is, inter alia, 
the fact that cell cultures have been found to have the ability to activate monocytes 
and increase IL-8 production by these cells [158, 160]. IL-8, as a pro-inflammatory 
chemokine, further acts as a chemoattractant on neutrophils and activates them 
[161]. This interleukin is considered one of the major mediators in the pathogenesis 
of IPF, and its higher serum concentrations and BAL of these patients are associated 
with more extensive pulmonary fibrosis [162].
The results of a study conducted by Mills et al. indicate that IPF patients did not 
show a significant increase in serum antiHSP-72 antibodies compared to healthy 
subjects, nor did the concentration of the identical immunoglobulins differ between 
IPF and other interstitial lung diseases. However, in the bronchoalveolar lavage, 
an increase in the concentration of total antibodies (classes G, A, and M), but not 
of class G itself, is associated with a better disease outcome, i.e., it was observed 
in patients with slower disease progression [163]. These results contrast with the 
data from the previous study, which showed that the increase in the concentration 
of autoantibodies to HSP-70 in IPF patients was associated with a poor disease 
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outcome [164]. This discrepancy in the conclusions can be justified by applying 
different methods, i.e., the antigens used to isolate antibodies and the non-homoge-
neous groups in the research of Kahloon et al. in terms of age, gender and ethnicity. 
It is undeniable that these proteins and autoantibodies directed at them have their 
place in the pathogenesis of IPF, but further research is needed to elucidate the role 
and potential use of these biomarkers in pulmonary fibrosis.
5.11 YKL-40
YKL-40 is a glycoprotein, a member of the chitinase and chitin-like protein 
family, expressed in many tissues, especially those characterized by high metabolic 
activity [165]. The exact biological role of YKL40 is not fully known, but it is 
involved in various pathophysiological processes as an inflammatory glycoprotein, 
including cell proliferation, migration, and tissue remodeling [166].
YKL-40 is mainly expressed in alveolar epithelial cells and macrophages, and its 
values are elevated in the serum and lungs of patients with IPF [165]. In addition, 
high concentrations of YKL-40 are detected in other diseases accompanied by high 
levels of fibrosis, such as liver cirrhosis, Crohn’s disease, and systemic sclerosis 
[165]. Elevated levels of YKL-40 in serum and bronchoalveolar lavage are associated 
with a higher risk of death in patients with IPF, although there is a weak correlation 
between these concentrations [104]. Also, YKL-40 values are inversely related to 
lung function in asthma, sarcoidosis, and IPF [165]. YKL-40 is not a marker specific 
for IPF, although the cut-off value of 79 ng/ml is mentioned in the literature and 
associated with a poorer prognosis [105]. Compared to the short-term prognostic 
markers SP-D and CCL18, YKL-40 has the highest predictive value 3–4 years after 
diagnosis, so a potential combination of these markers could allow a better assess-
ment of survival [165].
5.12 Vimentin/anti-vimentin antibodies
Vimentin is a cytoskeleton protein in cells of mesenchymal origin which is 
considered responsible for increased cell invasiveness so that one can assume its 
importance in fibroblast invasion into the so-called fibrous foci in the lungs of IPF 
patients [167]. This filament is essential to the process of wound healing, so its 
overexpression results in increased cell invasiveness and excessive scar tissue  
formation [167, 168].
Immunochemical staining of tissue samples from IPF patients showed that 
vimentin was significantly more expressed in the cells at the periphery of the 
fibrous focus than in the center. In the same study, it was found that in the fasting 
state, as an inducer of the autophagy process, fibroblasts originating from IPF 
patients expressed vimentin more than control group fibroblasts, while the process 
of autophagy was lacking [169].
The defect of the autophagy process has already been associated with the devel-
opment of idiopathic pulmonary fibrosis, where there is no removal of parts of the 
extracellular matrix by their implementation in autophagosomes and the destruc-
tion of these products after fusion with lysosomes [170, 171].
The antiangiogenetic, as well as the antitumor agent WFA (withaferin A), can 
bind to vimentin, covalently modify it, and cause its aggregation [172]. Treatment 
of IPF fibroblasts with this agent increased the number of autophagosomes in these 
cells, i.e., it stimulated autophagy. In addition, the expression of vimentin and type 
I collagen were reduced, and the inhibition of vimentin reduced the invasiveness of 
fibroblasts [169]. All these facts confirm the role of vimentin in pulmonary fibrosis 
and its importance in the progression of the disease.
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Various cells involved in the development of pulmonary fibrosis secrete vimen-
tin under the influence of TGF-β1 [173]. This secreted cytoskeletal protein was 
found in significantly higher IPF patients than in the healthy, control group [174]. 
Over-expression of otherwise immunologically inert molecules leads to their higher 
immunogenicity [175]. This is confirmed by the results of a 2017 study that proved 
anti-vimentin autoantibodies in IPF patients in a much higher concentration than is 
the case with other lung diseases and healthy subjects. Patients with poorer clinical 
and poor disease outcomes had higher circulating concentrations of anti-vimentin 
antibodies features [174].
5.13 T-lymphocytes
As mentioned above, the central event in the development of IPF is an excessive 
reaction to repeated damage to alveolar epithelial cells with the formation of scar 
tissue that replaces the functional one [176]. Pulmonary fibrosis was considered a 
non-immune disease, but more and more evidence speak in favor of the role of the 
immune system in initiating the onset of fibrotic changes, as well as in the progres-
sion of fibrosis.
Regulatory T-lymphocytes are CD4+ T-cells that participate in immunosuppres-
sion and prevent the development of an immune response to the body’s antigens 
(autotolerance) [177]. These cells can produce various cytokines, including IL-10 
and TGF-β1, and therefore may have the potential to both suppress and promote the 
onset of fibrotic changes [148].
Activation of these T-lymphocytes increases the expression of semaphorin 
seven, which has a chemotactic effect on macrophages, stimulates the production of 
proinflammatory cytokines, and regulates collagen production by fibrocytes [178]. 
Increased expression of semaphorin seven on regulatory T cells has been found in 
IPF [179].
The cell population of Th2 lymphocytes (T-helper cells) and their product IL-13, 
which have long been known to have a role in allergic diseases and the pathogenesis 
of asthma, are now also associated with the development of IPF. Namely, this 
interleukin affects the extracellular matrix production and induces tissue fibrosis, 
which has been shown in animal models, where increased expression of IL-13 had 
profibrotic effects [180]. Studies show an increased concentration of this cytokine 
in the blood of patients with IPF and the correlation of these concentrations with 
disease progression [181]. These claims are consistent with the results of studies 
performed on mice lacking the IL-13 gene in which the induction of pulmonary 
fibrosis by bleomycin was inhibited [182].
5.14 Soluble receptor for advanced glycosylated end products (sRAGE)
The soluble receptor for advanced glycation end-products (sRAGE) acts as a 
decoy for capturing advanced glycation end-products (AGEs) and inhibits the 
activation of the oxidative stress and apoptotic pathways. The study of Manichaikul 
et al. [183] found that adults with IPF have lower sRAGE levels. They were associ-
ated with greater disease severity and a higher death rate or lung transplant at one 
year compared with healthy controls. Additionally, lower plasma sRAGE levels 
in patients with IPF and other ILDs when compared with healthy controls Lower 
sRAGE levels were associated with disease severity. In their study, Cabrera Cesar 
et al. [184] provide evidence, for the first time, for the possible use of AGE as a 
differential diagnostic biomarker to distinguish between IPF and connective tissue 
disease-associated interstitial lung disease (CTD-ILD). The role of RAGE in human 
and experimental models of IPF did not fully understand [185].
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Machahua et al. [186] evaluated the AGEs, and sRAGE levels in serum as a 
potential biomarker in IPF, demonstrate that the increase of AGE/sRAGE ratio is 
higher in IPF. AGE/sRAGE increase correlates with respiratory functional progres-
sion (FVC and DLCO values); changes in serum AGEs and sRAGE correlated with 
% change of FVC, DLCO, and TLC during the follow-up.
No difference in AGE or RAGE expression was observed in lungs with non-
specific interstitial pneumonia compared to that in the controls. Levels of circulat-
ing AGEs also increased significantly in the lungs of patients with IPF compared to 
those with NSIP and normal control [187].
6. Markers of endothelial damage
Aberrant angiogenesis is implicated in the pathogenesis of pulmonary fibrosis, 
and mediators of this process are VEGF, endothelin 1, interleukin 8.
6.1 Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor-A (VEGF-A) is the predominantly expressed 
member of the VEGF family and is often denoted as VEGF. It is a tyrosine kinase 
glycoprotein and is one of the most potent factors that stimulate angiogenesis. 
VEGF is elevated in IPF compared with healthy controls [137, 188].
Barratt et al. [189] report that the levels of VEGF-A165b protein were found to be 
dramatically elevated in the lung tissue of patients with IPF, is produced mostly by 
the alveolar epithelium but also by macrophages, lymphocytes, and fibroblasts.
Ando et al. reported reduced VEGF-A in the BALF of IPF patients compared to 
controls [190]. VEGF-A levels in peripheral blood are associated with the severity 
and progression of IPF [191]. Enhanced expression of VEGF-A is correlated with 
increased alveolar-capillary density in non-fibrotic regions of IPF lungs [192].
Nintedanib, therapeutics for IPF, acts by targeting VEGF receptor signaling, 
slows IPF progression, but the utility of VEGF as a marker of treatment success is 
not determined [193, 194].
6.2 Endothelin 1 (ET-1)
Endothelin-1 (ET-1) is a vasoactive peptide that plays a central role in lung fibro-
sis. ET-1 drives fibroblast activation, proliferation, differentiation into myofibro-
blast - processes that lead to excessive collagen deposition [195]. Barlo et al. [196] 
revealed that ET-1 in serum was significantly increased in IPF patients compared 
with healthy control subjects until it was significantly decreased in bronchoalveolar 
lavage fluid (BALF).
6.3 Interleukin-8 (IL-8)
Interleukin-8 (IL-8) is produced by phagocytes when exposed to inflammatory 
stimuli and promotes angiogenesis [191]. IL-8 levels were significantly higher in 
IPF exacerbated patients, and an increase in IL-8 by one pg/ml increases the odds of 
death by 6.7% in IPF patients [197]. Schupp et al. [198] found significantly higher 
levels of IL-8 in BAL samples from IPF-AE patients compared to stable IPF patients. 
Xaubet et al. [199] found that the percentage of IL-8–positive bronchoalveolar 
lavage macrophages was significantly higher in areas of IPF lung with extensive 
fibrosis defined by HRCT scans compared with BALF from healthy volunteers.
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7. Multimarker approach
The literature supports the concept of combining multiple markers and/or 
clinical parameters in clinical decision support. Biomarker panels consisting of two 
or more suspected biomarkers may potentially indicate a higher likelihood of IPF 
than any single biomarker, more effectively differentiate IPF patients from healthy 
volunteers and patients with other pulmonary diseases, define prognosis at the time 
of diagnosis, identify responses to therapy.
For example, the improved predictive value of the combination of biomarkers 
SP-A and SP-D in IPF was observed [200]. Rosas et al. [86] found that the combina-
tion of serum MMP1 and MMP7 levels distinguish IPF from other chronic lung 
diseases more than either protein on its own. Also, the combination of five proteins 
(MMP-7, MMP-1, MMP-8, Insulin-like Growth Factor Binding Protein 1(IGFBP1) 
and tumor necrosis factor receptor superfamily, member 1a (TNFRSF1A)) could 
distinguish with high sensitivity and specificity IPF patients from normal controls. 
White et al. [63] showed that a combined serum biomarker panel combining 
SP-D, MMP-7, and osteopontin differentiated IPF patients from other types of ILD 
(except for rheumatoid arthritis–associated ILD) more readily than each biomarker, 
and this biomarker index may improve diagnostic confidence in IPF. Hamai et al. 
[201] found that a combination of MMP-7 and KL-6 potentially support the diag-
nosis of IPF and might improve survival prediction in patients with IPF. Recently 
published study Xue et al. [202], found that KL-6, CCL3, and CXCL13 significantly 
improves the diagnosis of idiopathic interstitial pneumonia. IPF patients with a 
high level of SP-D but low KL-6 in their serum had a better prognosis [203]. A panel 
of mi-RNAs including miR-302c, miR-423, miR-210, miR-376C, and miR-185 has 
been shown to be associated with disease severity, differentiating fast from slow IPF 
progressors [204].
The next step was to examine the combination of clinical parameters and molec-
ular biomarkers to achieve more accurate results regarding the prognosis of IPF. 
Kinder et al. [84] reported on a significant improvement in their prediction model 
of 1-year mortality in surgical lung biopsy-proven IPF, when serum levels of SP-A 
and SP-D were added to the clinical predictors of mortality alone [205]. Richards 
et al. [206] evaluated a panel of 92 proteins in a retrospective derivation cohort of 
IPF patients and tested significant findings in an independent validation cohort of 
IPF patients, and identified five biomarkers (MMP-7, intercellular adhesion mol-
ecule-1, Interleukin-8, vascular cell adhesion protein −1, S100A12) associated with 
disease progression or mortality. Combining clinical parameters and plasma protein 
concentrations (gender, FVC%, DLCO%, MMP-7), they constructed peripheral 
blood risk index-PCMI, distinguishing high and low mortality risk subgroups in 
the derivation was accurately predictive of mortality in the validation cohort. Song 
et al. [65] found that the predictive model of survival includes biomarkers (MMP7, 
SPA, KL6) and clinical variables (FVC%, DLCO%, age, change in FVC at six 
months) is better than the model based on clinical parameters.
Herazo-Maya et al. [207] have recently identified a 52-gene signature in periph-
eral blood mononuclear cells of patients with IPF, and y further validated in six 
different cohorts of patients with IPF. They developed a SAMS (Scoring Algorithm 
for Molecular Subphenotypes) risk scoring system based on the 52-gene signature. 
Applying SAMS, low risk and high-risk groups of IPF patients with significant dif-
ferences in outcome (mortality or transplant-free survival). This 52-gene signature 
could be valuable in predicting response to therapy.
In testing the idea that a combination of clinical and biological parameters 
can improve IPF patients’ outcomes prediction, Adegunsoye et al. [208] derived a 
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clinical-molecular risk (CMR) score (CA-125, MMP7, YKL-40, OPN, age, and percent 
predicted FVC) for treatment exposed patients. They found that a clinical-molecular 
signature of IPF transplant-free survival may provide a reliable predictor of outcome 
risk in anti-fibrotic treated patients. This risk score may help identify individuals at 
risk of poor outcomes despite antifibrotic initiation and open the discussion of the 
application of CMS risk score before initiation of antifibrotic therapy to identify 
patients warranting closer clinical monitoring or earlier lung transplant referral [209].
8. Conclusions
Within the last decade, a broad range of molecular biomarkers for IPF has been 
reported. Until now, despite a large number of publications about IPF biomark-
ers, their use in routine is not recommended in international clinical practice yet. 
The successful translation of molecular biomarkers into clinical practice requires 
validation in large, multi-center, prospective studies with long-term, longitudinal 
follow-up, standardization of assays, serial measurements of biomarkers, and 
interventional trials that show changes related to clinical IPF state.
However, most data about IPF biomarkers originate from small-sized, single-
center studies of the retrospective design, cross-sectional with measurements at a 
single time-point, and often in Asiatic cohorts of patients where their use is more 
common. This raises questions about the generalizability of the results obtained 
in Asiatic cohorts as well as about the determination of an optimal cut-off. Their 
accuracy should also be confirmed in non/Asiatic, Caucasian cohorts to routinely 
apply them in the management of IPF.
Furthermore, diagnostic criteria for IPF have recently changed, and most of the 
studies published before did not systematically use HRCT or histology. However, 
using these stringent criteria, confident data regarding biomarkers value could be 
obtained. Also, the gold standard for measuring disease activity is missing.
The validation of useful and accurate diagnostic markers could reduce uncer-
tainty and the use of the invasive procedure. Inter-assay disagreement can represent 
a confounding factor in the interpretation of test results in different studies, and the 
definition of an optimal cut-off is very important.
Finally, as already touched on in the chapter, investigators are resorting to panels 
of multiple biomarkers to differentiate IPF patients more effectively from healthy 
volunteers or patients with other pulmonary diseases. The use of a biomarker 
index composed of multiple biomarkers already studied separately, with the aim 
of improving diagnostic accuracy in distinguishing IPF from other ILDs or healthy 
controls, is promising.
There is evidence of extremely strong genetic association in IPF. Recent advances 
in genetic sequencing and bioinformatics have made it much easier to detect genetic 
variants rapidly. It seems that in the near future, we will be able to analyze genetic 
markers to gain prognostic information for IPF patients or help screen at-risk 
patients with a familial history that do not exhibit signs or symptoms of IPF.
The utilization of high-throughput sequencing to detect microbial and/or viral 
genetic material in bronchoalveolar lavage fluid or lung tissue samples has amplified 
the ability to identify and quantify specific microbial and viral populations [210].
Use of liquid biopsy, which allows the isolation of circulating cell-free DNA from 
blood, could be very important in the discrimination of patients affected by IPF 
from those with other ILDs [211].
Discovery, validation, and implementation of clinically useful molecular 
biomarkers discovered through omics (genomics, epigenomics, transcriptomics, 
proteomics, and metabolomics) will facilitate precision medicine in IPF [212–214].
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